Investigation on the Therapeutic Mechanism of Danbie Capsules for Endometriosis: A Network Pharmacology Approach

Lina Zhang, Ruibin Wu, Tenghui Ma, Wenwen Fu, Jiamin Chen, Lingling Li, Qing He
International journal of general medicine · 2024 · vol. Volume 17 , pp. 2557–2574 · doi:10.2147/ijgm.s451119 · PMID:38855423 · PMC11162222 · W4399328065
article OA: gold CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study identified Quercetin, β-sitosterol, and Luteolin as key active substances in Danbie Capsules for endometriosis, targeting TP53 and AKT1.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This study used a network pharmacology workflow to identify Danbie Capsules’ putative active substances and endometriosis-related targets, integrating compounds from TCMSP and literature (screened by oral bioavailability and drug likeness) with differentially expressed genes from GEO dataset GSE25628 and protein–protein interaction data from STRING. The authors reported three critical active substances (quercetin, β-sitosterol, and luteolin) and seven key targets, highlighting TP53 and AKT1, with support from molecular docking and immunohistochemical verification of TP53/AKT1 in rectal ectopic versus normal endometrium samples from 6 patients per group. A major limitation noted by the approach itself is that the results rely heavily on in silico target prediction and pathway enrichment, with small histology sample sizes and no functional causal experiments described. This paper is centrally about endometriosis — it investigates Danbie Capsules’ active components and predicted molecular targets (TP53, AKT1) using network pharmacology and validation experiments.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

OBJECTIVE: To explore the active substances and targets of Danbie Capsules in Endometriosis therapy. METHODS: This study was conducted through TCMSP and published literature screened and obtained 183 active substances of Danbie Capsules, combined and intersected with Endometriosis target genes collected and screened in the GEO database, obtained 24 target genes for Endometriosis treatment, and mapped the target network map of Danbie Capsules active substances against Endometriosis. The network was analyzed with the aid of Cytoscape version 3.9.1. With the aid of the platform of the STRING data analysis, PPI network analysis was conducted on 24 anti-Endometriosis targets of the Danbie Capsules. RESULTS: The research results obtained three critical active substances, namely, Quercetin, β-sitosterol, and Luteolin. Seven critical targets were identified, and two representative genes (TP53 and AKT1) have been verified in Macromolecular docking and immunohistochemical verification. CONCLUSION: The active substances of Danbie Capsules in the treatment of Endometriosis are Quercetin, β-sitosterol and Luteolin, and the main targets are TP53 and AKT1.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

References (12)

Source provenance

europepmc
last seen: 2026-06-22T06:15:23.361955+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pmc
last seen: 2026-05-17T02:30:03.883495+00:00
pubmed
last seen: 2026-06-22T06:13:25.010825+00:00
License: CC0 · commercial use OK